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Abstract
Chemokines (CK) provide directional cues that mediate the
recruitment of leukocytes to sites of inflammation. Broad-
spectrum blockade of the CC-CK family, using the vaccinia
virus 35K protein, has been shown to cause a potent reduction
of systemic inflammation in models of atherosclerosis, vein
graft disease and arthritis. We have used a cell membrane-
targeted form of 35K, Mem35K, to probe whether cell-
associated blockade of chemokine response is sufficient to
reduce cell recruitment in inflammation. In Tie2cre mice,
activation of a flox-stop Mem35K transgene directed condi-
tional expression of Mem35K in leukocytes and endothelial
cells, confirmed by Western blotting, flow cytometry and
immunofluorescence microscopy. This conditional Mem35K
expression was sufficient to increase cell surface CCL5 bind-
ing and reduce chemotaxis in vitro to CCL5, CCL2 and CCL3
but not to non-CC-CK chemoattractants, LTB4, C5a or
chemerin. However, in vivo monocyte recruitment into the
peritoneum driven by zymosan or CC-chemokine injection,
which was demonstrated to be CC-CK dependent using CCR2
−/− mice, was not reduced by Mem35K expression, despite
the expression of functional Mem35K protein. These findings
highlight differing requirements for cell-associated anti-in-
flammatory activity in in vitro and in vivo models.
Key message
& Mem35K is a cell-associated CC-chemokine binding
protein.
& Conditional Mem35K transgenic mice show expression
Mem35K in leukocytes.
& Mem35K blocks in vitro primary macrophage chemotaxis
specifically towards CC-chemokines.
& Mem35K expression is not sufficient to reduce inflamma-
tion in vivo.
& The requirements for anti-inflammatory activity in vitro
and in vivo are different.
Keywords Chemokine .Macrophage . Therapy .
Inflammation . Transgenic
Introduction
CC-Chemokines (CC-CK) are a large class of low molecular
weight 8–12 kDa chemoattractant cytokines that predomi-
nantly mediate the migration of mononuclear cells [1]. CC-
CK ligate GPCR receptors, activating downstream signalling
and leading to cellular activation, cytoskeletal reorganisation
and migration [2]. Studies in mice deficient in CC-CK or their
receptors have demonstrated a pivotal role for CC-CK signal-
ling in mediating cell recruitment in multiple immune and
inflammatory models including atherosclerosis, experimental
autoimmune encephalomyelitis (EAE), asthma and graft ver-
sus host disease [3–6].
Viruses have evolved a portfolio of immune defence mol-
ecules that can block or modulate the mammalian chemokine
system. Pox family viruses express a soluble 35-kDa protein,
‘35K’, that binds and inactivates almost all members of the
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CC-chemokine family [7]. Analysis of the purified protein
shows it binds all human andmouse CC-CKwith high affinity
[8]. The crystal structure of 35K bound to CCL4 reveals that
when the chemokine is bound, the residues required for re-
ceptor binding are obscured [8]. Systemic treatment of ani-
mals with 35K via hepatic gene transfer or with a soluble Fc-
fusion protein form of this molecule is able to reduce disease
in models of atherosclerosis, fibrosis, arthritis and allergic
airway inflammation [7, 9–11]. The potency of this
chemokine-binding molecule makes it an attractive tool for
determining the role of CC-CK in disease models and for
probing the therapeutic potential of broad-spectrum CC-CK
blockade in experimental disease models. In cardiovascular
disease in particular, there is evidence that multiple CC-CK
and their receptors act in concert to promote atherosclerosis,
since CCR2−/−, CCR5−/− and CCL2−/− mice have all shown
reduced atherosclerosis in hyperlipidemic models [4, 12, 13].
Indeed, the combined inhibition of both CCL2 and CCL5
activity led to additive inhibition of atherosclerosis [13]. It is
not yet clear whether the potency of multiple CC-CK block-
ade is indicative of functional redundancy within the CC-CK
system or is a result of a complex pathology manifesting
through multiple parallel highly cell-specific roles for individ-
ual CC-CKs [14]. Indeed, small-molecule CC-CK inhibitors
are already being tested in clinical trials as therapies for
inflammatory diseases, but there is uncertainty as to whether
local, cell-specific or systemic inhibition of CC-CK action
will be necessary for clinical efficacy, whilst avoiding poten-
tially harmful effects on systemic immune function. Thus,
there remains a pressing need to understand how cell-
specific effects of CC-CK inhibition will impact on inflam-
matory cell recruitment.
To test the potential of CC-CK inhibition as an anti-
inflammatory strategy targeting individual cells, we have
engineered a novel, cell-localised form of the 35K chemokine
binding protein,Mem35K, that has a cell-restricted expression
pattern through a FasL transmembrane domain, facilitating
localization to membranes, and a green fluorescent protein
(GFP) moiety for cellular identification [15]. Cell transfection
studies and adenoviral delivery to the liver demonstrated that
high-level expression of this molecule is sufficient to reduce
the chemotaxis of Mem35k-expressing cells and can reduce
hepatic inflammation in the concavalin A model of hepatitis
[15]. However, adenoviral delivery of a cell-localised mole-
cule is a fundamentally limited strategy, since the principal
target of gene transfer techniques such as adenoviral delivery
is the liver. Whilst this is ideal for the production of secreted
molecules, or effects mediated by high-level hepatocyte trans-
gene expression, it does not allow the targeting of specific cell
types such as leukocytes. Furthermore, the important question
of whether CC-CK inhibition can be achieved at the level of
individual inflammatory cell populations, as distinct from
whole-organ or systemic effects, remains unknown.
To address these questions, we now report the development
of a system for cell- or tissue-restricted expression of
Mem35K, using a conditional transgenic mouse for expres-
sion of Mem35K under control of a CMV flox-stop promoter.
To evaluate the transgenic cell-localised expression of
Mem35K, we crossed these mice with transgenic mice ex-
pressing cre under control of the Tie2 promoter, in order to
direct transgenic Mem35 expression to leukocytes.
Materials and methods
Additional methods can be found in the Supplementary
Material.
Generation of the Mem35K transgenic mouse
The Mem35K mouse was commercially produced by
genOway (Lyon, France). The Mem35K cDNA was intro-
duced into the Hprt locus using the ‘Quick Knock-in’
targeting vector containing the CCAG promoter and a vali-
dated floxed STOP cassette [16] and the human HPRT allele
to reconstitute the Hprt gene. The targeting cassette was
linearised, isolated and purified prior to electroporation into
E14Tg2a ES cells derived from 129P2/Ola mice. Positive
selection was achieved by identification of HAT-resistant
clones. Southern blotting identified 9 ES cell clones that were
correctly targeted. The recombined ES cells were injected into
blastocysts from pseudopregnant C57bl/6J mice. Chimeric
male offspring with 80–100 % chimerism were selected for
breeding to confirm germline transmission. Two founder 80%
chimeric males demonstrated germline transmission and pro-
duced 8 female Mem35K heterozygous mice.
Results
Mem35K elicits GFP fluorescence, membrane-localised 35K
protein and reduces CC-chemokine receptor-mediated
chemotaxis
In order to validate the functional effects of the transgenic
Mem35K protein, HEK 293 cells were transfected with a
plasmid encoding Mem35K, incorporating intracellular N
terminal GFP and FasL transmembrane domains, fused with
extracellular 35K and C terminal HA epitope tag (Fig. 1a).
Western blotting of cells 24 h after transfection demonstrated
the presence of the expected 65-kDa Mem35K protein, which
was detected with antibodies targeted against either the HA
epitope tag or the 35K molecule (Fig. 1b). To confirm the
presence of GFP within the construct, fluorescence microsco-
py and flow cytometry were used to detect GFP (Fig. 1c, d).
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The cell membrane localisation and functional expression of
Mem35K were confirmed by confocal microscopy to visual-
ise the intracellular GFP, which showed a non-ubiquitous
localised distribution (Fig. 1c) within cell membranes through
the cell. To confirm the presence of mem35K expression on
the cell surface membrane, which is required for activity, we
performed flow cytometry with an anti-HA antibody and
demonstrated cell surface HA in the Mem35K-transfected
cells (Fig. 1d). To test the effects of Mem35K molecule on
chemotaxis towards biologically relevant stimuli, we com-
pared the chemotaxis of HEK 293 cells, transfectedwith either
CCR5 alone or co-transfected with CCR5 and Mem35K, in
response to plasma from ApoE−/− mice, which has high plas-
ma CC-CK activity. CCR5-transfected HEK 293 cells showed
significant migration towards ApoE−/− plasma, at either 2.5 or
5 % in chemotaxis buffer (Fig. 1e). This migration of CCR5-
expressing cells was significantly inhibited by cotransfection
withMem35K (p<0.05). The striking inhibition of chemotax-
is by Mem35K transfection, despite typical transfections effi-
ciencies of >50 %, is likely to indicate an inhibitory effect on
both the expressing cells and exertion of a bystander effect on
non-expressing cells, as we have documented previously [15].
Flow cytometry using an anti-CCR5 antibody confirmed
CCR5 expression was unchanged between groups (Fig. 1f).
Transgenic expression of Mem35K
To generate a transgenic mouse, the Mem35K transgene was
cloned into an expression cassette under control of the ubiq-
uitous CCAG promoter (CMV immediate early enhancer/
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Fig. 1 Confirmation of the Mem35K protein structure. a Schematic
representation of the Mem35K molecule. b Expression of a Mem35K
plasmid in HEK293 cells resulted in expression of a 65-kDa protein that
was detectable byWestern blotting with an anti-HA or anti-35K antibody
and absent in sham-transfected cell lysates (loading control GAPDH).
Positive controls of a cell line stably expressing the GTCPH-HA mole-
cule and recombinant 35K-Fc protein were used to confirm antibody
specificity. c Transfected cells showed endogenous GFP fluorescence
with a membrane-associated expression pattern. (scale bar 2 um). d To
confirm cell surface expression of a proportion of theMem35Kmolecule,
transfected HEK293 cells underwent cell surface staining with anti-HA
antibody or isotype control (grey histogram). Endogenous GFP fluores-
cence was also quantified to confirm transfection. e Functional Mem35K
expression was confirmed by coexpression in a CCR5 bioassay, with
migration of CCR5 expressing HEK 293 cells towards ApoE−/− plasma
being inhibited by coexpression of the Mem35K molecule. (*p<0.05,
cells assayed in duplicate towards n=3 independent plasma samples per
experiment and replicated in two independent experiments). f Cells co-
transfected with Mem35K or empty vector and CCR5 expressed similar
levels of CCR5 on the cell surface, as detected by flow cytometry using
an anti-CCR5 antibody
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chicken β-actin promoter fusion). A loxP flanked STOP cas-
sette was included between the promoter and the Mem35K
transgene to allow conditional gene expression (Fig. 2a). The
Mem35K transgene was targeted to the Hprt locus, on the X
chromosome, by homologus recombination. To ascertain the
integrity of the flox-stop system, Mem35Kflox mice were
crossed with mice expressing cre under control of the Tie2
promoter (Tie2cre mice). These mice express cre in a shared
haematopoietic/endothelial progenitor population, resulting in
cre-mediated DNA deletion in all mature leukocytes arising
from this population, as well as in endothelial cells [17, 18].
Tie2cre also demonstrates cre expression in the female
germline; thus, only male Tie2cre animals are used for breed-
ing to maintain conditional gene expression [18, 19]. Primers
were designed to detect both the floxed and excised Mem35K
alleles. InMem35Kflox Tie2cre mice, conditional gene expres-
sion was demonstrated with earsnip DNA showing only the
floxed product, but in macrophages there was efficient cre-
mediated production of the excised allele (Fig. 2b). To con-
firm that the CCAG promoter was able to drive Mem35K
protein production, immunoprecipitation was performed
using anti-HA conjugated agarose beads in lysates produced
from primary peritoneal macrophages elicited by Biogel from
Mem35Kflox Tie2cre mice (Fig. 2c). NoMem35K protein was
detected in the absence of cre expression, indicating that the
STOP cassette efficiently prevented gene expression. In ani-
mals co-expressing cre, immunoprecipitatedMem35K protein
was detected using either anti-HA or anti-35K antibodies in
Western blotting. Furthermore,Mem35K protein was detected
by immunoprecipitation in the lungs, where endothelial cells
and leukocytes are abundant, but was below the limits of
detection in organs such as the liver where other cell types
predominate (Fig. 2d).
Functional transgenic expression of Mem35K detected
in vitro
To further investigate the expression and localization of
Mem35K protein in cells from Mem35Kflox Tie2cre mice,
we performed fluorescence confocal microscopy on primary
macrophages ex vivo, which had demonstrated Mem35K
protein expression by Western blotting. Endogenous GFP
fluorescence was detected in Biogel-elicited peritoneal mac-
rophages frommice expressingMem35K, by both significant-
ly increased green fluorescence by flow cytometry (Fig. 2e)
and confocal microscopy (2F), although expression was not
sufficiently high to show clear localization of the transgene
within the cell. The localization of mem35K to the cell surface
was confirmed by detection of the HA epitope on the cell
surface by flow cytometry (2F). The presence of active
mem35K on the cell surface was confirmed by detection of
significantly increased biotinylated CCL5 binding to the cell
surface (Fig. 2f). Mem35Kflox Tie2cre mice yielded
macrophages with a greater binding capacity for CCL5. Fur-
thermore, we confirmed that this effect was not due to alter-
ations in cell surface chemokine receptor expression by de-
tecting no significant difference in CCR5 expression on the
cell surface using an anti-CCR5 antibody (Fig. 2f). In primary
endothelial cells from Mem35Kflox Tie2cre mice, identified
using anti-CD31 immunohistochemistry, expression of the
Mem35K molecule was revealed by anti-GFP immunohisto-
chemistry, but only in Mem35Kflox Tie2cre mice that carried
both the Mem35K and Tie2cre transgenes (Fig. 2f). Endothe-
lial expression of Mem35K was also demonstrated using anti-
GFP immunohistochemistry in the aorta from Mem35Kflox
Tie2cre mice, compared to non-expressing controls (Fig. 2f).
We next tested the effects of Mem35K transgene expres-
sion on chemotaxis in primary macrophages ex vivo, first
using a modified Boyden chamber assay. We first confirmed
that the peritoneal recruitment of macrophages using Biogel as
a eliciting agent was not altered by the expression of
Mem35K. No significant difference in the number of mature
F4/80 expressing macrophages recruited to the cavity was
observed by flow cytometry (Fig. 3a, b). Macrophages from
animals that did not express Mem35K protein demonstrated a
dose-dependent chemotaxis towards both the CC-CK, CCL5
and to the non-CC-CK chemoattractant, LTB4 (Fig. 3c). Mac-
rophages expressing Mem35K protein showed a significant
reduction of the chemotactic response to the CCL5 (P<0.05),
whereas transgenic Mem35K expression did not affect the
chemotactic response to LTB4. This inhibition of ex vivo
chemotaxis is not due to alterations in CCR5 expression,
which was unchanged (Fig. 2f). To further test the ability of
Mem35K to specifically inhibit CC-chemokine-mediated che-
motaxis, we utilised a real-time macrophage chemotaxis assay
based on electrical cell impedance (ACEA Biosciences,
xCELLigence). In these experiments, chemotaxis of
Mem35K expressing macrophages was reduced to the CC-
chemokines CCL2, CCL3 and CCL5 (P<0.05), but not to the
non-CC-CK chemoattractants, chemerin or C5a (Fig. 3d, e).
Taken together, these data demonstrate thatMem35K express-
ing primary macrophages from Mem35Kflox Tie2cre mice
show a selective inhibition of CC-CK-mediated chemotaxis.
Functional expression of Mem35K in vivo
Having demonstrated that transgenic expression of Mem35K
by macrophages was sufficient to reduce CC-CK-mediated
chemotaxis in vitro, we next tested experimental models of
peritonitis to probe the ability of Mem35K to reduce chemo-
taxis in vivo. As chemokines have been shown to control
leukocyte homeostasis, cell counts of the major circulating
leukocyte populations were assessed in blood, bone marrow
and spleen (Table 1) [20]. No significant alteration in the
number of monocytes, neutrophils or lymphocytes was ob-
served, confirming in vivo experiments would not be
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confounded by alterations in leukocyte homeostasis. To assess
in vivo cell recruitment, Mem35Kflox Tie2cre and
Mem35Kflox control animals were injected intraperitoneally
with 100 μg zymosan. Peritoneal lavage was performed after
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Fig. 2 Production of a Mem35K expression transgenic mouse. a Sche-
matic representation of the Mem35K-floxed allele in both the floxed and
cre-excised form. Genotyping primers are shown: shared primer as black
arrows, the floxed allele is formed by primers marked as the black and red
arrows and the excised allele by the black and green arrows with the
dotted green arrow representing a longer PCR product that is not pro-
duced by the black and green primers in the absence of cre-mediated
excision of the floxed DNA segment. b PCR analysis of genomic DNA
extracted fromMem35K-floxed animals in the presence or absence of the
Tie2cre transgene showed the excised ‘active’ allele is not detected in ear
snip DNA, but it is efficiently detected in primary macrophages. c
Immunoprecipitation using anti-HA agarose beads followed by Western
blotting identified a protein product only in Biogel-elicited macrophages
from animals carrying both the Mem35Kflox and Tie2cre transgenes,
identified using both an anti-35K and anti-HA antibody. Positive controls
GTPCH-Ha (anti-HA) and recombinant 35K-Fc (anti-35K). d The
Mem35K protein was detectable by anti-HA immunoprecipitation
followed byWestern blotting using an anti-HA antibody in protein lysates
from endothelial and leukocyte-rich lung tissue and not from liver in
animals carrying bothMem35Kflox and Tie2cre. e Primary Biogel-elicited
macrophages from Mem35Kflox Tie2cre animals showed significantly
higher GFP fluorescence than Mem35Kflox animals by flow cytometry
(n=6 per genotype, *p<0.05) as well as significant expression of the HA
epitope on the cell surface (n=3 per genotype, *p<0.05). The expression
of the CCR5was unchanged (n=3), but theMem35KfloxTie2cre animals
demonstrated greater CCL5 binding to the cell surface (isotype or control
protein binding shown in grey) (n=6, *p<0.05). f Immunofluorescence
confocal microscopy demonstrated endogenous GFP fluorescence in
Biogel-elicited macrophages that was not present in the absence of cre.
Anti-GFP immunofluorescence demonstrated GFP expression in primary
endothelial cells and aortic sections from Mem35Kflox Tie2cre animals.
Scale bar 10 um
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16 h to recover the recruited cells (Fig. 4a). The cells recruited
were quantified by flow cytometry, using an absolute counting
protocol. Zymosan induced the recruitment of high numbers
of both monocytes and neutrophils at 16 h (Fig. 4b). However,
there was no significant difference in the number of cells
recruited in the Mem35Kflox Tie2cre or control animals. The
recruitment of monocytes in this model was confirmed to be
CC-CK dependent by performing a parallel experiment in
CCR2−/− mice, which demonstrated a near total lack of
recruitment (Fig. 4c).
Because 100 μg zymosan generates a potent sterile inflam-
mation that takes 96 h to resolve, we next investigated a less
potent model of peritonitis in order to determine whether the
lack of effect of Mem35K was due to the production of
inflammatory cytokines overwhelming the inhibitory capacity
of cell-associated Mem35K. Mice were injected with 10 μg of
zymosan for 4 h to evaluate at early leukocyte recruitment
(Fig. 4d). Injection of zymosan caused recruitment of neutro-
phils and monocytes after 4 h in both Mem35K-expressing
and non-expressing controls. However, no significant effect
on the number of neutrophils or monocytes recruited was
observed. Again the CC-CK dependence of this model was
confirmed using CCR2−/− mice, which demonstrated a sig-
nificant decrease in monocyte recruitment in this model
(Fig. 4e and Supplementary Figure 1).
To directly assess whether Mem35K can inhibit specific
CC-chemokines in vivo, we injected CCL2 i.p., which has
previously been shown to cause monocyte recruitment to the
peritoneal cavity [21]. Injection of 2 μg CCL2 caused a
significant recruitment of both monocytes and neutrophils
after 4 h, but no effect of Mem35K expression was seen on
the recruitment of either population (Fig. 4f). Although CCL2
would be assumed to cause recruitment via the receptor
CCR2, we confirmed no confounding effect of the injection
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Fig. 3 Functional expression of
the Mem35K transgene. Flow
cytometry using anti-F4/80
antibody and hemacytometer total
peritoneal exudate cell counts
indicated that the composition (a)
and number of Biogel-elicited
macrophages (b) was not altered
inMem35Kflox/Tie2cre animals. c
Modified Boyden chamber che-
motaxis assays using Biogel-
elicited macrophages demonstrat-
ed a significant reduction in che-
motaxis to CCL5, but not to the
chemoattractant LtB4. d Further
chemotaxis studies using the
xCELLigence real-time chemo-
taxis system demonstrated a sig-
nificant inhibition of chemotaxis
towards CCL5 but not towards
C5a. A representative trace from
the RTCA-DP software of Biogel-
elicited macrophages migrating
towards chemoattractant or buffer
alone control is shown. e Quanti-
fication of the response in the
xCELLigence assay showed mi-
gration towards CCL5, CCL2 and
CCL3, but not towards C5a or
chemerin was significantly
inhibited. (n=5/6 per genotype
(Boyden chamber assay) or n=3/
4 per genotype (xCELLigence
assay), two-way ANOVA,
*p<0.05)
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procedure on monocyte recruitment and confirmed the nature
of the recombinant protein injected by performing a parallel
experiment in CCR2−/− mice. We demonstrated no recruit-
ment of monocytes to CCL2 in CCR2−/− mice, confirming
this model is working via CC-CK as expected; however, the
migration of neutrophils was unaffected by the loss of
CCR2 indicating they are migrating in response to other
substances in the recombinant protein preparation (Fig. 1g and
Supplementary Figure 1).
Discussion
These studies provide new and important insights to the
application of CC-CK inhibition as a cell-specific therapeutic
strategy in inflammatory diseases. These new insights were
gained through cell-localised expression of a broad-spectrum
CC-CK inhibitor by leukocytes and endothelial cells in trans-
genic mice, using the flox-stop conditional expression system.
Transgenic expression of the Mem35K CC-CK inhibitor pro-
tein was readily detectable and sufficient to significantly in-
hibit leukocyte recruitment in in vitro models of chemotaxis.
However, this cell-localised expression of the CC-CK inhib-
itor protein did not reduce leukocyte chemotaxis in an in vivo
model of inflammation. These observations suggest that cell-
restricted CC-CK inhibitors will not be sufficient to limit
chemotaxis of inflammatory cells in vivo and that more sys-
temic approaches to limit CC-CK action will be required.
Previous studies with a soluble, secreted form of 35K have
shown potent effects on inflammatory cell recruitment [9,
22–24]. Furthermore, high-level viral-mediated expression
ofMem35K in the liver is able to reduce hepatic inflammation
induced by Concavalin A [15], demonstrating that the cell-
restricted expression of Mem35K can also suppress the mi-
gration of leukocytes [15]. However, whether this effect of
Mem35Kwas achieved through competition for CC-CK bind-
ing at the surface of individual cells or through local seques-
tration of CC-CK in tissue could not be determined, as in vivo
studies were limited to un-targeted local expression through
adenoviral gene delivery, rather than through cell-targeted
expression in the responder population of leukocytes.We have
now achieved cell-targeted expression of Mem35K in leuko-
cytes rather than hepatocytes that are the predominant target of
adenoviral gene delivery. In transgenic leukocytes ex vivo, we
again demonstrated that expression of the Mem35K is suffi-
cient to reduce chemotaxis. In contrast, this reduced sensitiv-
ity to chemokine was not sufficient to alter leukocyte recruit-
ment in a model of peritonitis in vivo. This finding suggests
that the ability of a cell-targeted CC-CK inhibitor to exert an
anti-inflammatory effect in vivo is more reliant on the ability
of the molecule to sequester chemokines in the tissue, rather
than by exerting a selective and cell-specific inhibition of
chemokine receptor signalling at the surface of individual
leukocytes. Such a cell-selective inhibition of chemokine
signalling by Mem35K may require higher expression—it is
of note that the migration of Mem35K-transfected cells to-
wards CC-CK is almost completely ablated in our previous
study, but is only blunted in our transgenic leukocytes [15].
Alternatively, cells expressing Mem35K in vitro may show a
more potent inhibition of CC-CK as they are ‘produced’ in a
system that lacks CC-CK, therefore enabling the full comple-
ment of Mem35K to bind exogenously applied CC-CK, in
contrast to cells in vivo, where cumulative saturation of
Mem35K by CC-CK may ultimately diminish any functional
impact on inflammatory cell recruitment.
Analysis of the structure of 35K bound to CCL4 reveals
that 35K binds the residues responsible for CC-CK receptor
binding. As a result, chemokines bound to 35K are unable to
activate downstream signalling. We have previously shown
that soluble 35K protein present in plasma binds chemokine
and renders it inactive by demonstration that whilst chemo-
kine levels in plasma are not decreased, or even are increased,
in 35K expressing animals, that the chemokine mediated
biological activity of those fluids is reduced [9, 24].
Clear evidence that the expression of a competitor for CC-
CK binding is sufficient to regulate inflammation is provided
by the D6 decoy chemokine receptor that regulates the reso-
lution of inflammation by scavenging chemokines. Whilst
D6−/−mice do not show any obvious phenotype in the absence
of an inflammatory challenge, these mice show a significant
increase in concentration of its ligands in plasma and inflamed
tissue and the development of a more severe inflammatory
response [25, 26]. This action of D6 demonstrates that
Table 1 Leukocyte counts from blood, spleen and bone marrow in
Mem35Kflox and Mem35Kflox/Tie2cre animals were obtained by flow
cytometry
Mem35Kflox Mem35Kflox/Tie2cre
Blood (cells×106/ml)
Neutrophils 0.30 (±0.06) 0.44 (±0.06)
Monocytes 0.21 (±0.04) 0.25 (±0.06)
T cells 1.81 (±0.49) 2.29 (±0.59)
B cells 1.34 (±0.11) 1.30 (±0.15)
Spleen (cells×106)
Neutrophils 0.73 (±0.08) 0.83 (±0.05)
Monocytes 0.73 (±0.22) 0.87 (±0.22)
T cells 11.9 (±2.04) 9.38 (±0.88)
B cells 17.5 (±4.56) 17.5 (±5.62)
Bone marrow (cells×106)
Neutrophils 4.16 (±0.35) 5.15 (±0.67)
Monocytes 0.94 (±0.10) 1.44 (±0.26)
No significant effect ofMem35K expression on homeostatic cell numbers
was observed. (n=7/8)
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expression of a cell-surface CC-CK binding molecule is a
mechanism by which inflammation can be regulated in vivo.
Given this is the case, then it may follow that Mem35K, in
addition to the level of expression that can be achieved by a
single copy transgene, may lack other features of its regulation
that are required to act in this fashion. D6 undergoes rapid
recycling between the plasma membrane to the endosome;
however, in contrast to chemokine receptors that also inter-
nalise following ligand binding, D6 surface expression is not
downregulated by prolonged exposure to its ligand [27].
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Fig. 4 Function of theMem35K transgene in vivo. Mice were injected ip
with inflammatory stimuli, zymosan or CCL2, and recruited cells recov-
ered at the given timepoints by peritoneal lavage. Flow cytometry was
used to quantify the number of neutrophils and monocytes recruited. a
Representative flow cytometry data from peritoneal exudates demonstrate
the identification of monocytes (7/4HI, Ly-6G−) and neutrophils (7/4HI,
Ly-6G+) in PBS and zymosan-treated animals (100 ug for 16 h).
Mem35Kflox/Tie2cre or CCR2−/− were treated with zymosan 100 μg
for 16 h (b, c) or 10 μg for 4 h (d, e) and the number of recruited
monocytes and neutrophils counted. To more directly assess CC
chemokine-mediated cell recruitment, mice were injected ip with 2 μg
CCL2 and peritoneal lavage was performed after 4 h (f, g). See Supple-
mentary Figure 1 for neutrophil quantification in CCR2−/− mice. (n=4–6
per group (Zymosan/CCL2; n=1–3 saline-injected animals included per
genotype to confirm an absence of pre-existing inflammation), *p<0.05
by T test between genotype in zymosan/CCL2-treated animals)
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Indeed, there is little evidence that D6 activity is regulated by
expression, rather that changes in the rate of cell surface
recycling allows increased activity during inflammation [28].
Mem35K lacks an intracellular signalling domain, so is unable
to undergo the controlled endocytic process used by D6. In-
stead, membrane expression can only be controlled by gene
expression, using a CMV-driven promoter that is not highly
regulated by inflammation [29]. The successful expression by
adenovirus of this protein may be in part due to the high level of
expression that is present acutely following infection. The fate
of CC-CK once bound to 35K or Mem35K is unknown, so
whether the binding capacity of each individual molecule is
rapidly exhausted is key to understanding the utility of this
molecule in therapy. If each molecule can only bind a single
CC-CK molecule (as suggested by the co-crystal structure with
CCL4), then a key aspect of this therapy is in sustaining a
continuous high level of ‘free’Mem35K. The binding capacity
of Mem35K is not exhausted during the development and
circulation of the transgenic leukocytes as the primary Biogel-
elicited cells still demonstrate an in vitro phenotype. The
Mem35Kflox/Tie2cre mouse also exhibits expression in endo-
thelial cells, and despite this additional expression, whichmight
be expected to exert a bystander effect on active chemokine
availability, no in vivo reduction of inflammation is seen.
Although we have not probed the functionality of the endothe-
lial cell-expressed Mem35K in detail, we would hypothesise
that the limitations of the level and non-regulated manner of
expression would apply as they do to the leukocyte-expressed
molecule.
Therapies that act by competition can be an effective strat-
egy, since anti-TNF targets the soluble component to compete
with TNF action at a systemic level [30]. However, it is likely
that cell-targeted therapies must be potent and regulated by
inflammation, if they are a competitive inhibitor, or block the
cell-autonomous part of the pathway such as the receptor.
Furthermore, such a strategy is likely to require a sustained,
high level of unbound inhibitor in order to exert a functional
effect (as exemplified by viral delivery systems), but as a
purified protein may be expensive and require frequent dosing.
In conclusion, expression of the cell-associated CC-CK
inhibitor, Mem35K, by leukocytes effectively inhibits CC-
CK action in vitro, but this cell-associated inhibition of CC-
CK is not effective in blockade of leukocyte recruitment
in vivo. Strategies to reduce inflammation by CC-CK binding
will require high-level CC-CK binding to reduce CC-CK
action in the whole tissue or systemically, making cell-
targeted CC-CK inhibition strategies less likely to be effective
as a therapeutic strategy.
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